Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) EVP Dana Aftab sold 1,508 shares of Exelixis stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $39.00, for a total value of $58,812.00. Following the completion of the transaction, the executive vice president now owns 693,181 shares of the company's stock, valued at approximately $27,034,059. This represents a 0.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Exelixis Price Performance
Shares of Exelixis stock opened at $39.84 on Tuesday. The firm's 50-day moving average is $37.00 and its two-hundred day moving average is $35.20. Exelixis, Inc. has a 1 year low of $20.14 and a 1 year high of $40.26. The stock has a market cap of $10.98 billion, a price-to-earnings ratio of 22.51, a PEG ratio of 1.13 and a beta of 0.25.
Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, equities analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.
Hedge Funds Weigh In On Exelixis
Several institutional investors and hedge funds have recently added to or reduced their stakes in EXEL. Blue Trust Inc. grew its position in shares of Exelixis by 134.7% in the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock worth $476,000 after buying an additional 8,208 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Exelixis in the fourth quarter worth $17,046,000. Range Financial Group LLC acquired a new position in shares of Exelixis during the fourth quarter worth $994,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock valued at $52,884,000 after purchasing an additional 704,786 shares during the last quarter. Finally, Inspire Investing LLC boosted its position in shares of Exelixis by 25.0% in the 4th quarter. Inspire Investing LLC now owns 36,659 shares of the biotechnology company's stock worth $1,221,000 after purchasing an additional 7,331 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts have recently commented on the company. Citigroup lifted their target price on Exelixis from $38.00 to $45.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Royal Bank of Canada lifted their price objective on shares of Exelixis from $38.00 to $40.00 and gave the stock an "outperform" rating in a research note on Thursday, March 13th. Guggenheim reiterated a "buy" rating and set a $42.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. JMP Securities restated a "market outperform" rating and issued a $41.00 target price on shares of Exelixis in a report on Thursday, April 17th. Finally, StockNews.com upgraded shares of Exelixis from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $37.59.
Get Our Latest Research Report on Exelixis
Exelixis Company Profile
(
Get Free Report)
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
